Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50 Day Moving Average - What's Next?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) shares crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.79 and traded as low as $0.68. Karyopharm Therapeutics shares last traded at $0.70, with a volume of 998,124 shares.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on KPTI. StockNews.com cut Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. Piper Sandler raised their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.

Karyopharm Therapeutics Trading Down 3.4 %

The stock has a market capitalization of $85.34 million, a P/E ratio of -0.59 and a beta of 0.05. The firm's fifty day moving average is $0.79 and its 200-day moving average is $0.83.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the firm posted ($0.30) EPS. Equities research analysts expect that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in KPTI. Geode Capital Management LLC boosted its stake in shares of Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock valued at $1,125,000 after purchasing an additional 43,856 shares during the last quarter. FMR LLC boosted its stake in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company's stock valued at $307,000 after acquiring an additional 76,510 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock worth $1,474,000 after acquiring an additional 792,283 shares during the period. Exchange Traded Concepts LLC raised its position in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock valued at $182,000 after acquiring an additional 56,613 shares during the last quarter. Finally, Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $31,000. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).